InvestorsHub Logo
Followers 8
Posts 3893
Boards Moderated 1
Alias Born 06/28/2005

Re: ontheedge01 post# 9959

Thursday, 03/16/2006 8:29:04 PM

Thursday, March 16, 2006 8:29:04 PM

Post# of 45771
"What has happened is a company who cannot get their stuff going, is looking to hitch a ride with a company that is getting their stuff going."

Edge, are talking about ASD? McKesson Pharmacueticals has exclusive marketing rights.

ASD has designed an automated validation system specifically for scanning pills. They have choosen to penetrate a high-end niche market.

McKesson has been placing ASD automated prescription validation systems into central fill location pharmacies way before Valimed got in their first hospital.

CDEx has designed a manual validation system specifically designed to scan compounded solutions. Valimed is cost effective for use in hospital pharmacies. Valimed has a very specific low-end niche market.

No one is hitching a ride with anyone Edge. Each is targeting entirely different market segments using portions of the electromagnetic spectrum best suited for each of their applications IMO.

Will they eventually compete with each other down the road in the same market segment? Probably, best get this over with so they can both get on with business.















Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.